RecruitingPhase 2NCT05604131

Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients


Sponsor

Rohan Dharmakumar

Enrollment

89 participants

Start Date

Nov 8, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

The objective of this randomized, controlled pilot study is to determine the efficacy of Deferiprone to reduce the amount of free iron inside the hemorrhagic zone of myocardial infarction among hemorrhagic myocardial infarction patients.


Eligibility

Min Age: 18 YearsMax Age: 79 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Deferiprone Tablets and a drug called Placebo for people with acute myocardial infarction (type 1). The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 79 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDeferiprone Tablets

Deferiprone tablets are the active medication for the active arm of the study groups. Randomization will be done by investigational drug services pharmacist and intervention will be double-blinded to investigators and patients.

DRUGPlacebo

Deferiprone placebo is the non-medicated formulation for a control arm of the study groups.


Locations(1)

IU Methodist Hospital (IUHealth)

Indianapolis, Indiana, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05604131


Related Trials